High-Cost Medicines in Thailand: A Global Perspective and Policy Recommendations
By Danélia Botes
November 15, 2023
The Rising Cost of Medical Interventions
Novel medical interventions have emerged from scientific advancements, offering better quality and extended life for patients with life-threatening conditions. These interventions include gene therapies and tissue-engineered medicines that target various cancers, rare, and ultra-rare diseases. However, the medicines come with an extremely high cost. In 2022, the top ten most expensive medicines ranged from USD 600,000 to over USD 3.5 million per dose. This high cost puts a significant financial burden on households. Consequently, it can reduce, delay, or even deny access to potentially life-saving care.
The Dilemma of High-Cost Medicines
There is currently no universally agreed-upon definition of high-cost medicine. Medicines often get described as those whose Incremental Cost-Effectiveness Ratio (ICER) goes beyond the public’s willingness-to-pay threshold for a Quality-Adjusted Life Year (QALY). Including these medicines in a public health insurance scheme’s benefits package means a high opportunity cost for a health system. If we increase the budget for public purchase, it results in withdrawing resources from private consumption through taxation or other methods.
The Thai Approach to High-Cost Medicines
Thailand, an upper middle-income country in Southeast Asia, uses Health Technology Assessment (HTA), including cost-effectiveness analysis, to guide the development of its pharmaceutical benefits package, the National List of Essential Medicine (NLEM). Over the years, there has been increasing pressure to include medicines deemed cost-ineffective. A study was therefore commissioned to provide recommendations for the management of such medicines as part of the Universal Coverage Scheme (UCS) Benefit Package (UCBP).
International Experiences and Recommendations
The study revealed that countries have established alternative mechanisms for reimbursing high-cost medicines. These mechanisms require particular eligibility criteria to be met, such as disease severity, rarity, the effectiveness of medicines, treatment of a life-threatening condition, and the absence of alternative treatment options. The study also proposed a framework for reimbursing high-cost medicines in Thailand, which involves creating a new sub-category, “E3”, for the NLEM to access high-cost medicine under the benefit package.
Conclusion and Key Message
Public health insurance schemes should only reimburse high-cost medicines when they are cost-effective. Countries may consider reimbursing non-cost-effective high-cost medicines only when they save lives or lack alternative treatment options. Monitoring and evaluation of implementation arrangements will be critical for assessing the impact of these programmes.
🚀 Discover how the AI-driven LabelComp tool is transforming drug safety surveillance! By automating the identification of adverse events in drug labelling, LabelComp enhances accuracy and efficiency, supporting regulatory decision-making and public health. 🌐💊 #SyenzaNews #AIinHealthcare #DrugSafety #PharmaInnovation #RegulatoryScience
🌟 School-based health centres (SBHCs) are improving healthcare for underserved youth across the US! These centres provide vital services, from preventive care to chronic disease management, right where students need them most – in schools. 📚🏥
SBHCs improve academic performance, reduce absenteeism, and enhance overall student well-being. Let’s support these essential centres and ensure every child has access to quality healthcare. 🌟
🌟 Exciting developments in Abu Dhabi! The Department of Health has introduced new ABA guidelines for Autism Spectrum Disorder, aiming to improve care for People of Determination. This initiative focuses on standardising care, enhancing accessibility, and fostering collaboration between healthcare and education professionals. Learn more about how these guidelines can make a difference in the lives of individuals with ASD. #SyenzaNews #HealthcareInnovation #AutismCare #InclusiveHealth #ABAGuidelines #AbuDhabiHealth
When you collaborate with VSH Foundation, it's like unlocking a new dimension in healthcare
innovation.
Our research synergizes with your vision, combining expertise in health economics, policy analysis, advanced
analytics, and AI applications in healthcare. You’ll witness the fusion of cutting-edge methodologies and real-
world impact, as we work together to transform healthcare systems and improve patient outcomes globally.